EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The role of OX40 ligand/OX40 axis signalling in atopic dermatitis

Emma Guttman-Yassky, Michael Croft, Bob Geng, Natalie Rynkiewicz, Davide Lucchesi, Mark Peakman, Cassandra van Krinks, Wendell Valdecantos, Heming Xing, Stephan Weidinger

British Journal of Dermatology · 18.09.2024 · 191 (4) · 488-496

DOI: 10.1093/bjd/ljae230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Dermatology, online erschienen am 05.06.2024. Verfasst von Emma Guttman-Yassky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, OX40 Ligand, Receptors, OX40, Signal Transduction. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary Atopic dermatitis (AD) (also known as atopic eczema) is a common skin disease caused by inflammation, and affects 2–3 of every 10 people worldwide. AD affects people of all ages and can cause a range of symptoms, including dry thickened skin, itchiness, rashes and pain. Despite the recent addition of new targeted treatment options, there is still a need for new treatments for people with moderate-to-severe AD. New drugs are being studied that target two important signalling molecules in the immune system, called OX40 ligand (OX40L) and OX40. OX40L and OX40 bind together to continue the cycle of immune system activation, leading to increasing symptoms of AD. Blocking the OX40L and OX40 interaction may ease or stop symptoms of AD. This review outlines what is currently known about the causes of AD, including the role played by the immune system and specifically the role of OX40L and OX40. We also highlight the development of new treatments that target the OX40L and OX40 interaction to treat AD, and suggest what the future may hold for managing AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicOX40 LigandReceptors, OX40Signal TransductionHumansCytokinesAntigen-Presenting Cells

Substanzen

OX40 LigandReceptors, OX40CytokinesTNFRSF4 protein, humanTNFSF4 protein, human

Autor:innen und Institutionen

  • Departments of Dermatology and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY, USA.
  • La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Department of Allergy and Immunology, University of California, San Diego, CA, USA.
  • Sanofi, Cambridge, UK.
  • Sanofi, Cambridge, MA, USA.
  • Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.

Förderung

  • Sanofi

Zitieren

APA

Guttman-Yassky, E., Croft, M., Geng, B., Rynkiewicz, N., Lucchesi, D., Peakman, M., van Krinks, C., Valdecantos, W., Xing, H., & Weidinger, S. (2024). The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. British Journal of Dermatology, 191(4), 488-496. https://doi.org/10.1093/bjd/ljae230

Vancouver

Guttman-Yassky E, Croft M, Geng B, Rynkiewicz N, Lucchesi D, Peakman M, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. British Journal of Dermatology. 2024;191(4):488-496. doi:10.1093/bjd/ljae230

BibTeX
@article{GuttmanYassky2024,
  author = {Guttman-Yassky, Emma and Croft, Michael and Geng, Bob and Rynkiewicz, Natalie and Lucchesi, Davide and Peakman, Mark and van Krinks, Cassandra and Valdecantos, Wendell and Xing, Heming and Weidinger, Stephan},
  title = {The role of OX40 ligand/OX40 axis signalling in atopic dermatitis},
  journal = {British Journal of Dermatology},
  year = {2024},
  volume = {191},
  number = {4},
  pages = {488--496},
  doi = {10.1093/bjd/ljae230}
}
Kostenlos starten →